SOUTH SAN FRANCISCO, Calif., April 3 /PRNewswire/ -- Onmark, a national group purchasing organization (GPO) for community-based practices and an OTN company, today announced that it has signed new contracts with Pfizer for Camptosar(R) (irinotecan) and with Berlex for Leukine(R) (sargramostim). With these additions, Onmark offers its members contracts from 17 pharmaceutical manufacturers, representing the majority of the most widely-used chemotherapy, biologic and supportive care agents, including both brand and generic products.
"Pfizer and Berlex recognize the momentum Onmark has gained over the last two years in enrolling more than 2,300 community-based practice members and in greatly expanding our contract portfolio," said Clark Avery, Vice President and General Manager of Onmark. "These two leading pharmaceutical manufacturers understand that we have proven our value as a GPO through numerous educational programs, practice management tools and clinical resources that are focused on helping physicians, nurses and practice administrators understand the most appropriate and cost-effective use of the pharmaceutical products they administer in their clinics."
"Onmark's contracts with Pfizer and Berlex are unique in the community-based oncology market and offer members access to exclusive cost savings. These savings opportunities are increasingly important to physicians, given the rising costs of oncology drugs and the changing reimbursement climate," said Walter Kalmans, Vice President of Business Development for Onmark. "We are committed to helping community-based practices operate as cost-effectively and efficiently as possible so they can focus on providing optimal patient care."
One of the ways Onmark helps practices operate cost effectively is through Onmark Perform(TM), a high-touch compliance program for community-based practices that purchase more than $8 million annually through Onmark contracts. Practices that participate in the Onmark Perform Program have the opportunity to earn rebates and/or discounts on specific products based on established performance criteria. With today's announcement, Pfizer joins MGI Pharma, Novartis and Sanofi-Aventis as the fourth pharmaceutical manufacturer to offer contracts through the Onmark Perform Program.
About OTN
About Onmark
Onmark
